Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy
Sharon A Riddler, Evgenia Aga, Ronald J Bosch, Barbara Bastow, Margaret Bedison, David Vagratian, Florin Vaida, Joseph J Eron, Rajesh T Gandhi, John W Mellors, ACTG A5276s Protocol Team, Amy Mirand, Michael Klebert, Carrie Fry, Joan Dragavon, Susan Koletar, Mark Hite, Linda Meixner, Edward Seefried, Jorge L Santana Bagur, Sigrid Perez, Connie Funk, Bartolo Santos, Vicki Bailey, Brenda Jackson, Judith Feinberg, Michelle Saemann, Elizabeth Lindsey, Tamara James, Catherine Kronk, Jonathan Oakes, Mary Adams, Christine Hurley, Shelia Dunaway, Sheryl S Storey, Cornelius Van Dam, Kim Epperson, Pablo Tebas, Aleshia Thomas, Lisa Klevens, Sara Mattiucci, Trisha Walton, Jane Baum, Teresa Spitz, Debra DeMarco, Beverly E Sha, Tondria Green, Cathi Basler, Christine Griesmer, Judith A Aberg, Michelle S Cespedes, Sandra Valle, Debbie Slamowitz, Judith Currier, Vanessa Cajahuaringa, Babafemi Taiwo, Donna McGregor, Princy Kumar, Joseph Timpone, Mary Albrecht, Andrea Kershaw, Paul Sax, Cheryl Keenan, Eric Daar, Ruben Lopez, Annie Luetkemeyer, Jay Dwyer, Jerrold Ellner, Benjamin Linas, Valery Hughes, Luis Lopez-Detres, Traci Davis, Kim Whitely, Melody Palmore, Clifford Gunthel, Sharon A Riddler, Evgenia Aga, Ronald J Bosch, Barbara Bastow, Margaret Bedison, David Vagratian, Florin Vaida, Joseph J Eron, Rajesh T Gandhi, John W Mellors, ACTG A5276s Protocol Team, Amy Mirand, Michael Klebert, Carrie Fry, Joan Dragavon, Susan Koletar, Mark Hite, Linda Meixner, Edward Seefried, Jorge L Santana Bagur, Sigrid Perez, Connie Funk, Bartolo Santos, Vicki Bailey, Brenda Jackson, Judith Feinberg, Michelle Saemann, Elizabeth Lindsey, Tamara James, Catherine Kronk, Jonathan Oakes, Mary Adams, Christine Hurley, Shelia Dunaway, Sheryl S Storey, Cornelius Van Dam, Kim Epperson, Pablo Tebas, Aleshia Thomas, Lisa Klevens, Sara Mattiucci, Trisha Walton, Jane Baum, Teresa Spitz, Debra DeMarco, Beverly E Sha, Tondria Green, Cathi Basler, Christine Griesmer, Judith A Aberg, Michelle S Cespedes, Sandra Valle, Debbie Slamowitz, Judith Currier, Vanessa Cajahuaringa, Babafemi Taiwo, Donna McGregor, Princy Kumar, Joseph Timpone, Mary Albrecht, Andrea Kershaw, Paul Sax, Cheryl Keenan, Eric Daar, Ruben Lopez, Annie Luetkemeyer, Jay Dwyer, Jerrold Ellner, Benjamin Linas, Valery Hughes, Luis Lopez-Detres, Traci Davis, Kim Whitely, Melody Palmore, Clifford Gunthel
Abstract
We measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels by means of single-copy assay in 334 participants receiving virologically suppressive antiretroviral therapy (ART). A residual viremia load of ≥1 copy/mL after 4 years of ART was predicted by a higher pre-ART HIV-1 RNA level, higher CD8(+) T-cell count during treatment, and a lower ratio of CD4+ T cells to CD8+ T cells during treatment but not by initial ART regimen. In a longitudinal subset of 64 individuals, continued decay of the plasma HIV-1 RNA level was observed, with an average annual decrease of 6% and an estimated half-life of 11.5 years. In contrast to prior reports, the persistent viremia level continues to slowly decline during years 4-12 of suppressive ART.
Clinical trials registration: NCT00001137.
Keywords: CD4/CD8 ratio; HIV/AIDS; residual viremia; single-copy assay; viral decay.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
Figures
Source: PubMed